ArticleFrontiers in oncology2025

The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.

Fabio Efficace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.